Recent Updates
Recently added Catalysts
NBIX Positive Sentiment Score: 70/100

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2024 Financial Results Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2024 financial results conference call and...

Key Takeaway: Neurocrine Biosciences, Inc. (Nasdaq: NBIX) has announced a conference call and webcast to discuss its first quarter 2024 financial results, scheduled for May 1, 2024, at 5:00 a.m. PT. The press release will be made available at 4:00 a.m. PT that same day, and the live webcast can be accessed on the company's website. Following the event, a replay will be available for approximately one month.

Market Sentiment Analysis

POSITIVE FACTORS

  • Scheduled financial results indicate proactive communication to investors.
  • Planning for the conference call shows transparency and engagement.
  • The company’s commitment to addressing under-addressed neurological disorders reflects its focus on impactful healthcare solutions.

Full Press Release Details

Conference Call and Webcast Scheduled for Wednesday, May 1
SAN DIEGO , April 10, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced today that it has scheduled its first quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time ( 8:00 a.m. Eastern Time ) on May 1, 2024 .
The schedule for the press release and conference call / webcast is as follows:
Q1 2024 Press Release: May 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET
Q1 2024 Conference Call: May 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET
Domestic Dial-In Number: 800-343-4136
International Dial-In Number: 203-518-9814
Conference ID: NBIX
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com , and follow the company on LinkedIn , X (Formerly Twitter) and Facebook . (* in collaboration with AbbVie )
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
SOURCE Neurocrine Biosciences, Inc.

21 %

Frequently Asked Questions

When is Neurocrine's Q1 2024 conference call scheduled?

The conference call is set for May 1, 2024, at 5:00 a.m. PT.

How can I access the conference call and webcast?

Access the call via dial-in numbers or the Neurocrine website under Investors.

What is the domestic dial-in number for the conference call?

The domestic dial-in number is 800-343-4136.

What time will the Q1 press release be available?

The Q1 press release will be available at 4:00 a.m. PT on May 1, 2024.

How long will the webcast replay be available?

The webcast replay will be archived for about one month after the event.

Last updated: Apr 10, 2024